Triglyceride-rich lipoprotein cholesterol is elevated in liver transplant recipients and associated with post-transplant diabetes
Post-transplant diabetes mellitus (PTDM) is the most frequent metabolic complication after liver transplantation. The role of triglyceride-rich lipoprotein cholesterol (TRL-c) in PTDM risk remains poorly defined. We characterized TRL-c in liver transplant recipients (LTRs) from the TransplantLines cohort (NCT03272841) compared to the general population (PREVEND cohort; NCT03073018) and evaluated its association with incident PTDM. We compared 367 adult LTRs and 4,837 PREVEND participants with TRL-c measurements derived from total cholesterol, high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c), all measured by nuclear magnetic resonance spectroscopy. Incident PTDM was assessed using Cox models and adjusted for clinically relevant covariates. Compared with PREVEND participants, LTRs had higher triglycerides, TRL-c, and HDL-c but lower total and LDL-c, irrespective of baseline diabetes status. Among LTRs, TRL-c was highest in those with pre-existing diabetes and lowest in those who remained non-diabetic. During a median follow-up of 7.1 years (IQR 6.2-7.8), 31 (12.6%) LTRs developed PTDM. Incidence was highest in the top TRL-c tertile (p = 0.016). Each 1-SD increase in TRL-c was associated with a 64% higher PTDM risk, independent of other risk factors. TRL-c may help risk stratification after transplant, given it likely captures a dyslipidemic phenotype not represented by conventional lipid measurements.
Authors
- Henri G. D. Leuvenink (ORCID: https://orcid.org/0000-0001-5036-2999)
- António W. Gomes‐Neto (ORCID: https://orcid.org/0000-0002-4398-4877)
- Hubert G.M. Niesters (ORCID: https://orcid.org/0000-0002-1758-0430)
- Margery A. Connelly (ORCID: https://orcid.org/0000-0002-3917-592X)
- Jip Jonker (ORCID: https://orcid.org/0009-0006-9548-4985)
- Adrian Post (ORCID: https://orcid.org/0000-0001-8645-1627)
- Coretta van Leer-Buter
- Coby Annema (ORCID: https://orcid.org/0000-0001-8663-2145)
- Erik A.M. Verschuuren (ORCID: https://orcid.org/0000-0002-6807-6744)
- Bouke G. Hepkema (ORCID: https://orcid.org/0000-0002-3906-9887)
- S. Berger
- Eelko Hak (ORCID: https://orcid.org/0000-0003-0849-7210)
- Rianne M. Douwes (ORCID: https://orcid.org/0000-0002-2517-5769)
- Frank Klont (ORCID: https://orcid.org/0000-0003-3503-1694)
- Frank A.J.A. Bodewes (ORCID: https://orcid.org/0000-0003-0263-9791)
- Charlotte A. te Velde‐Keyzer (ORCID: https://orcid.org/0000-0002-8197-8056)
- Gertrude J. Nieuwenhuijs‐Moeke (ORCID: https://orcid.org/0000-0001-9874-2632)
- Riemer J H J A Slart
- Michel J. Vos (ORCID: https://orcid.org/0000-0001-9379-2219)
- M. H. De Borst
- Tim J. Knobbe (ORCID: https://orcid.org/0000-0003-3246-3192)
- Adelita V. Ranchor (ORCID: https://orcid.org/0000-0001-7048-3771)
- Yakun Li (ORCID: https://orcid.org/0000-0003-4048-572X)
- Marco van Londen (ORCID: https://orcid.org/0000-0001-7145-3240)
- Marion J. Siebelink (ORCID: https://orcid.org/0000-0001-5366-1732)
- Arjan Diepstra (ORCID: https://orcid.org/0000-0001-9239-1050)
- D. Kremer
- MICHIEL E. ERASMUS
- Han Moshage
- M. E. N. van den Heuvel
- Marieke T. de Boer (ORCID: https://orcid.org/0009-0008-0634-4740)
- Anna M Posthumus (ORCID: https://orcid.org/0009-0001-6520-6830)
- Rinse K. Weersma
- C. Tji Gan
- K Damman
- Robin Dullaart
- Gerard Dijkstra
- Michele F. Eisenga
- V de Meijer
- Willem S. Lexmond
- Stephan J. L. Bakker
- Caecilia S. E. Doorenbos
- Mateo Chvatal-Medina
- Hans Blokzijl
- Transplant Lines Investigators
- Jan Stephan F. Sanders
- L. Joost van Pelt
- J. Casper Swarte
- Daan J. Touw
- Robert A. Pol
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- LabCorp (United States) (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-07-17
- DOI
- https://doi.org/10.1038/s41598-026-62929-x
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hartstichting
- Nierstichting
- Astellas Pharma, Netherlands